A landmark study of more than 600,000 veterans published in the BMJ on March 4 found that GLP-1 medications like Ozempic and Mounjaro significantly reduce the risk of developing substance use disorders. Led by Dr. Ziyad Al-Aly at Washington University School of Medicine, the research showed a 14–25% lower risk of new addiction across alcohol, cannabis, cocaine, nicotine, and opioids compared to patients on SGLT2 inhibitors over three years.
The results were even more striking for people already struggling with addiction. GLP-1 users saw 29% fewer emergency department visits, 26% fewer hospitalizations, 39% fewer overdoses, and a 50% reduction in drug-related deaths. Scientists believe the drugs work by reaching GLP-1 receptors concentrated in the brain regions governing reward, motivation, and impulse control — the same circuits hijacked by addiction.
Researchers caution that randomized clinical trials are still needed before GLP-1 drugs can be prescribed specifically for addiction treatment. However, this is the first drug class to show potential benefit against multiple substance types simultaneously, marking a potential breakthrough in addiction medicine.
